Rituxan

(Rituximab)

Rituxan

Drug updated on 9/13/2023

Dosage FormInjection (intravenous; 100 mg/10 mL (10 mg/mL) and 500 mg/50 mL (10 mg/mL))
Drug ClassCD20-directed cytolytic antibody
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): relapsed or refractory, low grade or follicular, CD20-positive Bcell NHL as a single agent.
  • For the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
  • For the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
  • For the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
  • For the treatment of pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL): previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.
  • For the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL): previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
  • For the treatment of rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • For the treatment of granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis) and microscopic polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids.
  • For the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Rituxan (rituximab) Prescribing Information.2021Genentech, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of rituximab in multiple sclerosis : a systematic review and meta-analysis.2023Acta Neurologica Belgica
Rituximab in chronic immune mediated neuropathies: a systematic review.2022Neuromuscular Disorders
Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review.2022Frontiers in Immunology
The efficacy and safety of rituximab in ANCA-associated vasculitis: a systematic review.2022Biology
Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder : a systematic review.2022Multiple Sclerosis and Related Disorders
Different doses of rituximab for the therapy of neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.2022Multiple Sclerosis and Related Disorders
Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: a systematic review and meta-analysis.2022Frontiers in Pharmacology
The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and meta-analysis.2021BioMed Research International
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review.2021Autoimmune Reviews
Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis.2021Pancreatology
Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.2021Journal of Neurology
Use of rituximab in adults with relapsing–remitting multiple sclerosis : a systematic literature review2020Current Medical Research and Opinion
A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis.2020Medicine
Rituximab in the treatment of systemic sclerosis–related interstitial lung disease: a systematic review and meta-analysis.2020Rheumatology
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.2020BMJ Nephrology
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis : a systematic review and meta-analysis.2020Clinical Kidney Journal
Rituximab treatment for IgA vasculitis: a systematic review.2020Autoimmunity Reviews
The efficacy of rituximab in the treatment of refractory nephrotic syndr ome: a meta-analysis.2020International Urology and Nephrology
Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis : a systematic review and meta-analysis.2019Autoimmunity Reviews
Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders.2019Frontiers in Immunology
Rituximab in primary central nervous system lymphoma—a systematic review and meta-analysis.2019Hematological Oncology
Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis.2019International Journal of Rheumatic Diseases
The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis.2019Platelets
Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis.2018BioMed research International
Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.2018Rheumatology International
Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.2018The Journal of AABB Transfusion

Clinical Practice Guidelines